Revance Therapeutics | RVNC - Capitale Ordinario



Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 1.75B 2025-06
ALKERMES USD 165.61M 503K 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Cara Therapeutics USD 2K 3K 2025-03
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 946.83M 354.23M 2025-06
J&J USD 2.41B 584K 2025-09
Merck USD 2.49B 15.79M 2025-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
P&G USD 2.34B 1.67B 2025-12
Pacira USD 41.12M 1.85M 2025-12
Supernus Pharmaceuticals USD 57.12M 1000K 2025-09